Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Gross Profit (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Gross Profit for 16 consecutive years, with $19.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 11.99% to $19.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $63.8 million, a 1.69% decrease, with the full-year FY2025 number at $63.8 million, down 16.04% from a year prior.
  • Gross Profit was $19.2 million for Q4 2025 at Anika Therapeutics, up from $15.6 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $29.0 million in Q2 2023 to a low of $1.4 million in Q3 2024.
  • A 5-year average of $18.4 million and a median of $20.0 million in 2021 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: plummeted 94.23% in 2024, then soared 982.22% in 2025.
  • Anika Therapeutics' Gross Profit stood at $18.1 million in 2021, then crashed by 79.18% to $3.8 million in 2022, then surged by 52.93% to $5.8 million in 2023, then skyrocketed by 196.66% to $17.1 million in 2024, then rose by 11.99% to $19.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Gross Profit are $19.2 million (Q4 2025), $15.6 million (Q3 2025), and $14.4 million (Q2 2025).